12 studies found for:    3450848 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)
Condition: Healthy
Interventions: Drug: Daktavira;   Drug: Daklinza
2 Completed A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)
Condition: Healthy
Interventions: Drug: Elbanovir;   Drug: Sovaldi
3 Completed A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)
Condition: Healthy
Interventions: Drug: Doxirazole;   Drug: Dexilant
4 Completed A Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA)
Condition: Healthy
Interventions: Drug: Amlodipine/Valsartan;   Drug: Exforge
5 Completed A Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland)
Condition: Healthy
Interventions: Drug: Oseltamivir;   Drug: Tamiflu®
6 Completed Clinical Study Into the Cosmetic Results of Leukosan Adhesive
Condition: Wound Healing Cosmetic Result
Interventions: Device: Leukosan Adhesive;   Device: Transcutaneous suture
7 Completed Adductor Canal Block for Medial Compartment Knee Arthroplasty
Conditions: Postoperative Analgesia;   Medial Unicompartmental Knee Arthroplasty
Interventions: Procedure: Adductor canal block;   Procedure: Lumbar plexus block
8 Recruiting Impact of Early Post-Operative Water Exposure on Complications of Cutaneous Surgeries
Condition: Surgical Wound Infection
Intervention: Behavioral: Early Water Exposure
9 Completed A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol
Condition: Asthma
Interventions: Drug: SERETIDE Rotacaps;   Drug: SERETIDE Diskus
10 Completed A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia
Condition: Prostatic Hyperplasia
Interventions: Drug: Dutasteride (0.5mg, fasted state);   Drug: Dutasteride (0.5mg, fed state);   Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state);   Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state);   Drug: Harnal-D Tablets with water (fasted state);   Drug: Harnal-D Tablets with water (fed state);   Drug: Harnal-D tablets without water (fasted state)
11 Completed
Has Results
Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.
Condition: Asthma
Interventions: Drug: SERETIDE Rotacaps;   Drug: SERETIDE Diskus
12 Completed Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)
Condition: Healthy
Interventions: Drug: metformin ER;   Drug: metformin

Indicates status has not been verified in more than two years